R
Ribo Guo
Researcher at Novartis
Publications - 9
Citations - 1464
Ribo Guo is an academic researcher from Novartis. The author has contributed to research in topics: Smoothened & Smoothened Receptor. The author has an hindex of 7, co-authored 9 publications receiving 1329 citations.
Papers
More filters
Journal ArticleDOI
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Silvia Buonamici,Juliet Williams,Michael Morrissey,Anlai Wang,Ribo Guo,Anthony Vattay,Kathy Hsiao,Jing Yuan,John Green,Beatriz Ospina,Qunyan Yu,Lance Ostrom,Paul Fordjour,Dustin L. Anderson,John Monahan,Joseph Kelleher,Stefan Peukert,Shifeng Pan,Xu Wu,Sauveur Michel Maira,Carlos Garcia-Echeverria,Kimberly J. Briggs,D. Neil Watkins,Yung Mae Yao,Christoph Lengauer,Markus Warmuth,William R. Sellers,Marion Dorsch +27 more
TL;DR: By identifying a drug combination that delays or even combats development of resistance when used as a first-line treatment in clinical trials, these results could ultimately improve the lives of patients with medulloblastoma or other cancers that depend on Smo for their survival.
Journal ArticleDOI
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan,Xu Wu,Jiqing Jiang,Wenqi Gao,Yongqin Wan,Dai Cheng,Dong Han,Jun Liu,Nathan P. Englund,Yan Wang,Stefan Peukert,Karen Miller-Moslin,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Yun Jiang,Jeffrey Tsao,Fangxian Sun,AnneMarie Culazzo Pferdekamper,Stephanie Kay Dodd,Tove Tuntland,Wieslawa Maniara,Joseph Kelleher,Yung-mae Yao,Markus Warmuth,Juliet Williams,Marion Dorsch +27 more
TL;DR: Structural-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl- 3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.
Journal ArticleDOI
A crucial requirement for Hedgehog signaling in small cell lung cancer
Kwon-Sik Park,Luciano G. Martelotto,Martin Peifer,Martin L. Sos,Anthony N. Karnezis,Moe R. Mahjoub,Katie Bernard,Jamie F. Conklin,Anette Szczepny,Jing Yuan,Ribo Guo,Beatrice Ospina,Jeanette Falzon,Samara Bennett,Tracey Jean Brown,Ana Markovic,Wendy Devereux,Cory A. Ocasio,James K. Chen,Tim Stearns,Roman K. Thomas,Marion Dorsch,Silvia Buonamici,D. Neil Watkins,Craig D. Peacock,Julien Sage +25 more
TL;DR: Findings show a crucial cell-intrinsic role for Hedgehog signaling in the development and maintenance of SCLC and identify Hedgehog pathway inhibition as a therapeutic strategy to slow the progression of disease and delay cancer recurrence in individuals with S CLC.
Journal ArticleDOI
1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.
Karen Miller-Moslin,Stefan Peukert,Rishi K. Jain,Michael A Mcewan,Rajesh Karki,Luis Llamas,Naeem Yusuff,Feng He,Yanhong Li,Yingchuan Sun,Miao Dai,Lawrence Blas Perez,Walter Michael,Tao Sheng,Lei Huangshu,Rui Zhang,Juliet Williams,Aaron Bourret,Arun Ramamurthy,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Wieslawa Maniara,Adam Amaral,Marion Dorsch,Joseph Kelleher +26 more
TL;DR: A cell-based screen performed in the laboratories identified a new class of Hh pathway inhibitors, 1-amino-4-benzylphthalazines, that act via antagonism of the Smoothened receptor that displayed a good pharmacokinetic profile and also afforded tumor regression in a genetic mouse model of medulloblastoma.
Journal ArticleDOI
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/β-catenin signaling
Alix Scholer-Dahirel,Michael R. Schlabach,Alice Loo,Linda Bagdasarian,Ronald Meyer,Ribo Guo,Steve Woolfenden,Kristine Yu,Judit Markovits,Karen Killary,Dmitry Sonkin,Yung-mae Yao,Markus Warmuth,William R. Sellers,Robert A. Schlegel,Frank Stegmeier,Rebecca Mosher,Margaret McLaughlin +17 more
TL;DR: It is shown that active Wnt/β-catenin signaling is required for maintenance of colorectal tumor xenografts harboring APC mutations and this results support efforts to treat human coloreCTal cancer by pharmacological inhibition of the Wnt /β- catenin pathway.